康希諾生物(06185.HK)腦膜炎疫苗獲批上市
康希諾生物 (06185.HK)今早急升一成後中途停牌。國家藥監局網站顯示,康希諾生物的A群C群腦膜炎球菌多糖結合疫苗(CRM197載體)獲批上市,簽發日期為昨日(22日)。該腦膜炎疫苗為康希諾繼埃博拉疫苗、新冠疫苗後第三款上市的疫苗產品。
此外,商務部、工業和信息化部、衛生健康委、藥監局公布可供對外出口的新型冠狀病毒疫苗產品清單,上市許可持有人包括康希諾生物等四家公司。
商務部昨日亦公布中國企業研發生產、可供對外出口的新冠疫苗產品清單,康希諾的重組疫苗「克威莎」(Convidecia)上榜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.